Literature DB >> 18711953

Choosing a skeletal muscle relaxant.

Sharon See1, Regina Ginzburg.   

Abstract

Skeletal muscle relaxants are widely used in treating musculoskeletal conditions. However, evidence of their effectiveness consists mainly of studies with poor methodologic design. In addition, these drugs have not been proven to be superior to acetaminophen or nonsteroidal anti-inflammatory drugs for low back pain. Systematic reviews and meta-analyses support using skeletal muscle relaxants for short-term relief of acute low back pain when nonsteroidal anti-inflammatory drugs or acetaminophen are not effective or tolerated. Comparison studies have not shown one skeletal muscle relaxant to be superior to another. Cyclobenzaprine is the most heavily studied and has been shown to be effective for various musculoskeletal conditions. The sedative properties of tizanidine and cyclobenzaprine may benefit patients with insomnia caused by severe muscle spasms. Methocarbamol and metaxalone are less sedating, although effectiveness evidence is limited. Adverse effects, particularly dizziness and drowsiness, are consistently reported with all skeletal muscle relaxants. The potential adverse effects should be communicated clearly to the patient. Because of limited comparable effectiveness data, choice of agent should be based on side-effect profile, patient preference, abuse potential, and possible drug interactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18711953

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  10 in total

1.  Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain.

Authors:  Corey Witenko; Robin Moorman-Li; Carol Motycka; Kevin Duane; Juan Hincapie-Castillo; Paul Leonard; Christopher Valaer
Journal:  P T       Date:  2014-06

Review 2.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

3.  The FIBRO System: A Rapid Strategy for Assessment and Management of Fibromyalgia Syndrome.

Authors:  Chad S Boomershine
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

4.  High-throughput screening for modulators of cellular contractile force.

Authors:  Chan Young Park; Enhua H Zhou; Dhananjay Tambe; Bohao Chen; Tera Lavoie; Maria Dowell; Anton Simeonov; David J Maloney; Aleksandar Marinkovic; Daniel J Tschumperlin; Stephanie Burger; Matthew Frykenberg; James P Butler; W Daniel Stamer; Mark Johnson; Julian Solway; Jeffrey J Fredberg; Ramaswamy Krishnan
Journal:  Integr Biol (Camb)       Date:  2015-05-08       Impact factor: 2.192

5.  Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study.

Authors:  Ghadeer K Dawwas; Sean Hennessy; Colleen M Brensinger; Emily K Acton; Warren B Bilker; Sophie Chung; Sascha Dublin; John R Horn; Melanie M Manis; Todd A Miano; David W Oslin; Thanh Phuong Pham Nguyen; Samantha E Soprano; Douglas J Wiebe; Charles E Leonard
Journal:  CNS Drugs       Date:  2022-03-06       Impact factor: 6.497

6.  Fibromyalgia and myofascial pain syndrome-a dilemma.

Authors:  H C Chandola; Arunangshu Chakraborty
Journal:  Indian J Anaesth       Date:  2009-10

Review 7.  A symptom-based approach to pharmacologic management of fibromyalgia.

Authors:  Chad S Boomershine; Leslie J Crofford
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

8.  Optogenetic control of cellular forces and mechanotransduction.

Authors:  Léo Valon; Ariadna Marín-Llauradó; Thomas Wyatt; Guillaume Charras; Xavier Trepat
Journal:  Nat Commun       Date:  2017-02-10       Impact factor: 14.919

Review 9.  Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents.

Authors:  Ana Matošević; Anita Bosak
Journal:  Arh Hig Rada Toksikol       Date:  2020-12-31       Impact factor: 2.078

10.  Muscle relaxant use and the associated risk of incident frailty in patients with diabetic kidney disease: a longitudinal cohort study.

Authors:  Szu-Ying Lee; Jui Wang; Hung-Bin Tsai; Chia-Ter Chao; Kuo-Liong Chien; Jenq-Wen Huang
Journal:  Ther Adv Drug Saf       Date:  2021-06-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.